Effect of fluoroquinolones on the cardiovascular system of laboratory rabbits
N. V. Izmozherova,
V. M. Bakhtin,
A. A. Yakovleva,
M. A. Bashindzhagyan,
E. A. Makarov,
K. A. Kabanova https://doi.org/10.52420/2071-5943-2023-22-1-72-77
Abstract
Introduction. The use of fluoroquinolones is associated with prolongation of the QT interval on the cardiogram and increased risk of ventricular tachycardia. To study the mechanism of the cardiotoxic effect of fluoroquinolones and to develop methods of its prevention it is necessary to create models on laboratory animals.
The aim of the work was to analyze the effect of fluoroquinolones on the electrocardiographic parameters of laboratory rabbits.
Materials and methods. 20 rabbits were divided into 3 groups: 6 animals were control, 7 animals received ciprofloxacin 150 mg/kg for 14 days orally, 7 animals received levofloxacin 150 mg/kg for 14 days orally. Electrocardiography was performed before and after 14 days of drug exposure. P wave width, PQ interval, QRS complex, QT interval, corrected QT (QTc), RR interval were analyzed. Data are presented as median and interquartile range.
Results. Rabbits treated with ciprofloxacin showed a prolongation of the QTc interval compared with controls (QTc according to Bazett 306.2 (285.8; 319.8) versus 271.1 (255.2; 285.8) ms, p = 0.022; QTc according to Frederick 241.4 (225.3; 245.5) ms versus 219.1 (201.1; 225.3) ms, p = 0.022), as well as P wave shortening during the experiment (from 55.0 (50 .0; 70.0) ms to 40.0 (35.0; 50.0) ms, p = 0.027).
Discussion. Observed electrocardiographic changes indicate the ability of ciprofloxacin to accelerate atrial conduction, slow down ventricular myocardium repolarization and increase the risk of arrhythmias.
Conclusions. Oral ciprofloxacin administration at a dose of 150 mg/kg/day for 14 days simulates cardiotoxic effect in laboratory rabbits.
About the Authors
N. V. Izmozherova
Ural State Medical University
Russian Federation
Russian Federation
Nadezhda V. Izmozherova – Doctor of Science (Medicine), Associate Professor
Ekaterinburg
V. M. Bakhtin
Ural State Medical University
Russian Federation
Russian Federation
Viktor M. Bakhtin – Postgraduate student
Ekaterinburg
A. A. Yakovleva
Ural State Medical University
Russian Federation
Russian Federation
Anastasia A. Yakovleva – Student
Ekaterinburg
M. A. Bashindzhagyan
Ural State Medical University
Russian Federation
Russian Federation
Mikhail A. Bashindzhagyan – Student
Ekaterinburg
E. A. Makarov
Ural State Medical University
Russian Federation
Russian Federation
Egor A. Makarov – Student
Ekaterinburg
K. A. Kabanova
Ural State Medical University
Russian Federation
Russian Federation
Ksenia A. Kabanova – Student
Ekaterinburg
References
1. Mozhokina GN, Samoylova AG. Cardiac toxicity of fluoroquinolones and bedaquiline. Tuberculosis Lung Diseases 2019;97(4):56-62. (In Russ.) http://doi.org/10.21292/2075-1230-2019-97-4-56-62.
2. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001;21(12):1468–1472. http://doi.org/10.1592/phco.21.20.1468.34482.
3. Stancampiano FF, Palmer WC, Getz TW et al. Rare incidence of ventricular tachycardia and torsades de pointes in hospitalized patients with prolonged qt who later received levofloxacin: A retrospective study. Mayo Clin Proc 2015;90(5):606–612. http://doi.org/10.1016/j.mayocp.2015.02.011.
4. Gorelik E, Masarwa R, Perlman A et al. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug Saf 2019;42(4):529–538. http://doi.org/10.1007/s40264-018-0751-2.
5. Ushkalova EA, Zyryanov SK. Fluoroquinolone use restrictions in patients with uncomplicated infections and safety issues. Clinical Microbiology and Antimicrobial Chemotherapy = Kliniceskaa Mikrobiologia i Antimikrobnaa Himioterapia 2017;19(3):208–213. (In Russ.).
6. Khan F, Ismail M, Khan Q, Ali Z. Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review. Expert Opin Drug Saf 2018;17(10):1029–1039. http://doi.org/10.1080/14740338.2018.1520837.
7. Markova EV, Baturin SA, Ponomarev IA et al. Experimental evaluation of the fluoroquinolones effect on the QT interval in rabbits. Current Issues of Modern Medical Science and Public Health: Proceedings of the V International Scientific-Practical Conference (Ekaterinburg, April 9-10, 2020). 2020;3:545–550. (In Russ.) URL: http://elib.usma.ru/bitstream/usma/3487/1/USMU_Sbornik_statei_2020_3_131.pdf
8. Gus’kova TA, Hohlov AL, Romanov BK et al. Drug safety: from preclinic to clinic. Moskva ; Jaroslavl’: Aver pljus, 2018. 275 p. (In Russ).
9. Förster C, Schwabe R, Lozo E et al. Quinolone-induced arthropathy: exposure of magnesium-deficient aged rats or immature rats, mineral concentrations in target tissues and pharmacokinetics. Arch Toxicol 1997;72(1):26–32. http://doi.org/10.1007/s002040050464.
10. Stahlmann R, Förster C, Shakibaei M et al. Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical to quinolone-induced arthropathy. Antimicrob Agents Chemother 1995;39(9):2013–2018. http://doi.org/10.1128/AAC.39.9.2013.
11. Pfister K, Mazur D, Vormann J, Stahlmann R. Diminished ciprofloxacin-induced chondrotoxicity by supplementation with magnesium and vitamin E in immature rats. Antimicrob Agents Chemother 2007;51(3):1022–1027. http://doi.org/10.1128/AAC.01175-06.
12. Abo-Salem E, Fowler JC, Attari M et al. Antibiotic-induced cardiac arrhythmias. Cardiovasc Ther 2014;32(1):19–25. http://doi.org/10.1111/1755-5922.12054.
13. Sychev IN, Fedina LV, Sychev DA. Antibiotic therapy under polypragmatic conditions: a course to safety. Clinical Microbiology and Antimicrobial Chemotherapy = Kliniceskaa Mikrobiologia i Antimikrobnaa Himioterapia 2021;23(4):367–373. (In Russ.). http://doi.org/10.36488/cmac.2021.4.367-373.
14. Liu X, Ma J, Huang L et al. Fluoroquinolones increase the risk of serious arrhythmias: A systematic review and metaanalysis. Medicine (Baltimore) 2017;96(44):e8273. http://doi.org/10.1097/MD.0000000000008273.
15. Stahlmann R, Lode H. Toxicity of quinolones. Drugs 1999;58(2):37–42. http://doi.org/10.2165/00003495-199958002-00007.
16. Iannini PB. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin Drug Saf 2002;1(2):121–128. http://doi.org/10.1517/14740338.1.2.121.
17. Owens RCJr. QT prolongation with antimicrobial agents: understanding the significance. Drugs 2004;64(10):1091–1124. http://doi.org/10.2165/00003495-200464100-00005.
18. Poluzzi E, Raschi E, Motola D et al. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf 2010;33(4):303–314. http://doi.org/10.2165/11531850-000000000-00000.
19. Cho Y, Park HS. Association of oral ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin with the risk of serious ventricular arrhythmia: a nationwide cohort study in Korea. BMJ Open 2018;8(9):e020974. http://doi.org/10.1136/bmjopen-2017-020974.
20. Lapi F, Wilchesky M, Kezouh A et al. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis 2012;55(11):1457–1465. http://doi.org/10.1093/cid/cis664.
21. Keivanidou A, Arnaoutoglou C, Krommydas A et al. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. Cardiol J 2009;16(2):172–174.
22. Sanchez AC, Chohan M, Olatunde O, White C. A rare case of ciprofloxacin-induced bradycardia recognized by a smartwatch. J Investig Med High Impact Case Rep 2022;10:23247096211069761. http://doi.org/10.1177/23247096211069761.
Review
For citations:
Izmozherova NV, Bakhtin VM, Yakovleva AA, Bashindzhagyan MA, Makarov EA, Kabanova KA. Effect of fluoroquinolones on the cardiovascular system of laboratory rabbits. Ural Medical Journal. 2023;22(1):72-77. (In Russ.) https://doi.org/10.52420/2071-5943-2023-22-1-72-77
Views:
271
Email this article 